BACKGROUND: We conducted a preliminary retrospective evaluation of the efficacy and toxicity of proton-beam therapy (pbt) for stage iii non-small-cell lung cancer. METHODS: Between January 2009 and August 2013, 27 patients (26 men, 1 woman) with stage iii non-small-cell lung cancer underwent pbt. The relative biologic effectiveness value of the proton beam was defined as 1.1. The beam energy and spread-out Bragg peak were fine-tuned such that the 90% isodose volume of the prescribed dose encompassed the planning target volume. Of the 27 patients, 11 underwent neoadjuvant chemotherapy. Cumulative survival curves were calculated using the Kaplan-Meier method. Treatment toxicities were evaluated using version 4 of the Common Terminology Criteria for Adverse Events. RESULTS: Median age of the patients was 72 years (range: 57-91 years), and median follow-up was 15.4 months (range: 7.8-36.9 months). Clinical stage was iiia in 14 patients (52%) and iiib in 13 (48%). The median dose of pbt was 77 GyE (range: 66-86.4 GyE). The overall survival rate in the cohort was 92.3% at 1 year and 51.1% at 2 years. Locoregional failure occurred in 7 patients, and distant metastasis, in 10. In 2 patients, initial failure was both locoregional and distant. The 1-year and 2-year rates of local control were 68.1% and 36.4% respectively. The 1-year and 2-year rates of progression-free survival were 39.9% and 21.4% respectively. Two patients experienced grade 3 pneumonitis. CONCLUSIONS: For patients with stage iii non-small-cell lung cancer, pbt can be an effective and safe treatment option.
BACKGROUND: We conducted a preliminary retrospective evaluation of the efficacy and toxicity of proton-beam therapy (pbt) for stage iii non-small-cell lung cancer. METHODS: Between January 2009 and August 2013, 27 patients (26 men, 1 woman) with stage iii non-small-cell lung cancer underwent pbt. The relative biologic effectiveness value of the proton beam was defined as 1.1. The beam energy and spread-out Bragg peak were fine-tuned such that the 90% isodose volume of the prescribed dose encompassed the planning target volume. Of the 27 patients, 11 underwent neoadjuvant chemotherapy. Cumulative survival curves were calculated using the Kaplan-Meier method. Treatment toxicities were evaluated using version 4 of the Common Terminology Criteria for Adverse Events. RESULTS: Median age of the patients was 72 years (range: 57-91 years), and median follow-up was 15.4 months (range: 7.8-36.9 months). Clinical stage was iiia in 14 patients (52%) and iiib in 13 (48%). The median dose of pbt was 77 GyE (range: 66-86.4 GyE). The overall survival rate in the cohort was 92.3% at 1 year and 51.1% at 2 years. Locoregional failure occurred in 7 patients, and distant metastasis, in 10. In 2 patients, initial failure was both locoregional and distant. The 1-year and 2-year rates of local control were 68.1% and 36.4% respectively. The 1-year and 2-year rates of progression-free survival were 39.9% and 21.4% respectively. Two patients experienced grade 3 pneumonitis. CONCLUSIONS: For patients with stage iii non-small-cell lung cancer, pbt can be an effective and safe treatment option.
Entities:
Keywords:
Proton-beam therapy; chemotherapy; stage iii non-small-cell lung cancer
Authors: K Ando; Y Furusawa; M Suzuki; K Nojima; H Majima; S Koike; M Aoki; W Shimizu; Y Futami; T Ogino; S Murayama; H Ikeda Journal: J Radiat Res Date: 2001-03 Impact factor: 2.724
Authors: R Charles Nichols; Soon N Huh; Randal H Henderson; Nancy P Mendenhall; Stella Flampouri; Zuofeng Li; Harry J D'Agostino; J Davis Cury; Dat C Pham; Bradford S Hoppe Journal: Clin Lung Cancer Date: 2011-04-27 Impact factor: 4.785
Authors: Bradford S Hoppe; Stella Flampouri; Randal H Henderson; Dat Pham; Abubakr A Bajwa; Harry D'Agostino; Soon N Huh; Zuofeng Li; Nancy P Mendenhall; R Charles Nichols Journal: Clin Lung Cancer Date: 2012-01-20 Impact factor: 4.785
Authors: C A Perez; T F Pajak; P Rubin; J R Simpson; M Mohiuddin; L W Brady; R Perez-Tamayo; M Rotman Journal: Cancer Date: 1987-06-01 Impact factor: 6.860
Authors: W Sause; P Kolesar; I V Taylor S; D Johnson; R Livingston; R Komaki; B Emami; W Curran; R Byhardt; A R Dar; A Turrisi Journal: Chest Date: 2000-02 Impact factor: 9.410
Authors: W T Sause; C Scott; S Taylor; D Johnson; R Livingston; R Komaki; B Emami; W J Curran; R W Byhardt; A T Turrisi Journal: J Natl Cancer Inst Date: 1995-02-01 Impact factor: 13.506
Authors: Melissa A L Vyfhuis; Nasarachi Onyeuku; Tejan Diwanji; Sina Mossahebi; Neha P Amin; Shahed N Badiyan; Pranshu Mohindra; Charles B Simone Journal: Ther Adv Respir Dis Date: 2018 Jan-Dec Impact factor: 4.031